Skip to main content

LCD L37606: Genomic Sequence Analysis Panels in the Treatment of Hematolymphoid Diseases

LCD L37606, Genomic Sequence Analysis Panels in the Treatment of Hematolymphoid Diseases, is the Local Coverage Determination that Wellpoint Federal applies to claims from 10 states (CT, IL, MA, ME, MN, NH, NY, RI and others), effective 2026-04-01 and first in force 2018-08-01. The policy text runs 307 words, and its billing and coding article A56793 lists 89 ICD-10-CM codes that support medical necessity for 4 procedure codes. No other contractor publishes a policy with this title.

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database LCD export: MCD release November 12, 2026 (effective November 8, 2026); Medicare Coverage Database billing and coding articles: MCD release November 12, 2026 (effective November 8, 2026). Next CMS release: weekly, every Thursday.

Contractor
Wellpoint Federal
States and territories
10
CT IL MA ME MN NH NY RI VT WI
Revision effective
2026-04-01
Original effective
2018-08-01
Policy text
307 words
Covered ICD-10 codes (articles)
89

Where this LCD applies

Each contract number is a jurisdiction on the remittance; the policy binds claims processed under these contracts and no others.

Contracts that apply LCD L37606
ContractContractorTypeStates
06101Wellpoint FederalMAC - Part AIL
06201Wellpoint FederalMAC - Part AMN
06301Wellpoint FederalMAC - Part AWI
06102Wellpoint FederalMAC - Part BIL
06202Wellpoint FederalMAC - Part BMN
06302Wellpoint FederalMAC - Part BWI
13101Wellpoint FederalA and B and HHH MACCT
13201Wellpoint FederalA and B and HHH MACNY
13102Wellpoint FederalA and B and HHH MACCT
13202Wellpoint FederalA and B and HHH MACNY
13282Wellpoint FederalA and B and HHH MACNY
13292Wellpoint FederalA and B and HHH MACNY
14411Wellpoint FederalA and B and HHH MACRI
14211Wellpoint FederalA and B and HHH MACMA
14311Wellpoint FederalA and B and HHH MACNH
14511Wellpoint FederalA and B and HHH MACVT
14111Wellpoint FederalA and B and HHH MACME
14112Wellpoint FederalA and B and HHH MACME
14212Wellpoint FederalA and B and HHH MACMA
14312Wellpoint FederalA and B and HHH MACNH
14512Wellpoint FederalA and B and HHH MACVT
14412Wellpoint FederalA and B and HHH MACRI

Billing and coding article A56793: diagnoses and procedure codes

Since 2019 the codes live in the companion article rather than the LCD. Billing and Coding A56793 (Billing and Coding: Genomic Sequence Analysis Panels in the Treatment of Hematolymphoid Diseases) carries the diagnosis and procedure lists the contractor loads as the claims edit. CPT codes are shown as bare numbers because the descriptors are licensed by the AMA; HCPCS Level II descriptors are public and shown. Each article below opens its complete covered and non-covered ICD-10-CM lists, by group and with the contractor's group instructions, and the LCD code lookup answers whether one diagnosis is covered for one procedure code in a given state.

Coverage is only half of the claim edit: when two of the listed procedure codes are billed on the same date, test the pair against the NCCI edits before relying on both being paid.

A56793: Billing and Coding: Genomic Sequence Analysis Panels in the Treatment of Hematolymphoid Diseases (Billing and Coding, effective 2026-04-01)

Covered ICD-10-CM codes
89
3 groups
Non-covered ICD-10-CM codes
0
Procedure codes listed
4
Full article
cms.gov record
First 24 covered ICD-10-CM codes in A56793
ICD-10-CMDescription (FY2027)
C88.80Other malignant immunoproliferative diseases not having achieved remission
C92.00Acute myeloblastic leukemia, not having achieved remission
C92.02Acute myeloblastic leukemia, in relapse
C92.10Chronic myeloid leukemia, BCR/ABL-positive, not having achieved remission
C92.12Chronic myeloid leukemia, BCR/ABL-positive, in relapse
C92.20Atypical chronic myeloid leukemia, BCR/ABL-negative, not having achieved remission
C92.22Atypical chronic myeloid leukemia, BCR/ABL-negative, in relapse
C92.30Myeloid sarcoma, not having achieved remission
C92.32Myeloid sarcoma, in relapse
C92.40Acute promyelocytic leukemia, not having achieved remission
C92.42Acute promyelocytic leukemia, in relapse
C92.50Acute myelomonocytic leukemia, not having achieved remission
C92.52Acute myelomonocytic leukemia, in relapse
C92.60Acute myeloid leukemia with 11q23-abnormality not having achieved remission
C92.62Acute myeloid leukemia with 11q23-abnormality in relapse
C92.90Myeloid leukemia, unspecified, not having achieved remission
C92.92Myeloid leukemia, unspecified in relapse
C92.A0Acute myeloid leukemia with multilineage dysplasia, not having achieved remission
C92.A2Acute myeloid leukemia with multilineage dysplasia, in relapse
C92.Z0Other myeloid leukemia not having achieved remission
C92.Z2Other myeloid leukemia, in relapse
C93.00Acute monoblastic/monocytic leukemia, not having achieved remission
C93.02Acute monoblastic/monocytic leukemia, in relapse
C93.10Chronic myelomonocytic leukemia not having achieved remission

Procedure codes: 81450, 81451, 81455, 81456.

Coverage indications, limitations and medical necessity

Acute Myelogenous Leukemia (AML)

Indications

Genomic Sequential Analysis Panel will be considered reasonable and necessary in the evaluation of blood or bone marrow samples in the following clinical circumstances:

• Genomic Sequential Analysis Panel will be considered reasonable and necessary in the evaluation of blood or bone marrow samples for newly diagnosed or relapsed/refractory AML patients who are candidates for treatment, regardless of karyotype findings.

• Previously diagnosed patients with AML, who have not responded to induction chemotherapy, or who have progressed following induction. The patient must be a candidate for transplantation at the time of the testing.

• Patients with AML, who have responded to treatment, either chemotherapy or transplantation, with evidence of relapse.

Myelodysplastic Syndromes (MDS)

Indications

Genomic Sequential Analysis Panel will be considered reasonable and necessary in the evaluation of blood or bone marrow samples in the following clinical circumstances:

• Patients with clinical signs or symptoms of myelodysplastic syndromes (MDS) or myelodysplastic/myeloproliferative overlap syndromes (MDS/MPN), in whom clinical, laboratory, and pathologic assessment are nondiagnostic.

• Newly diagnosed MDS or MDS/MPN patients either

• stratified by the IPSS or IPSS-R as intermediate risk, or

• in MDS with ringed sideroblasts/RARS.

• Repeat Genomic Sequential Analysis Panel testing is considered reasonable and necessary in MDS after initial diagnosis and risk stratification.

Myeloproliferative Neoplasms (MPN)

Indications and Limitations of Coverage

Genomic Sequential Analysis Panel will be considered reasonable and necessary in the evaluation of blood or bone marrow samples in the following circumstances:

• Diagnosis: Clinical signs or symptoms of myeloproliferative neoplasm (MPN) or myelodysplastic/myeloproliferative overlap syndromes (MDS/MPN) when

• clinical, laboratory, and pathologic assessment are nondiagnostic; and

• CML excluded (BCR-ABL1 negative) 1,2

• Risk Stratification: Newly diagnosed PMF not already classified as high-risk by Dynamic International Prognostic Scoring System (DIPSS) Plus 1,3,4

• Monitoring: Higher-risk MF (INT-1, INT-2, High-Risk) with progression on therapy 1

Summary of evidence (opening)

Acute Myelogenous Leukemia (AML)

Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by the clonal expansion of myeloid blasts, primarily in the peripheral blood and bone marrow. The American Cancer Society estimates that approximately 60,000 new cases of leukemia will be diagnosed in 2016, with one-third classified as acute myelogenous leukemia (AML). It accounts for the most annual deaths from leukemia in the United States. The median age of diagnosis is 67, with 54% diagnosed at 65 years or older (and approximately one third diagnosed at 75 years of age or older). Moreover, AML lies at one end of a spectrum of neoplastic myeloid diseases that includes myelodysplastic syndromes (MDS), which often progress to AML, and which are even more common in patients of advanced age, with an incidence of approximately 1/5000 patients over the age of 70.

AML is an aggressive disease that requires immediate diagnosis and treatment, with an average 5 yr survival rate of 28%, depending on a number of clinical and biologic variables, including acquired genetic alterations within the leukemic cells. Early treatment of AML generally consists of high-dose cytotoxic chemotherapy to induce remission, followed by consolidation (i.e., post-remission) chemotherapy and/or bone marrow transplantation.

Steadily accumulating genomic evidence shows that certain acquired genetic alterations within the leukemic cells are strong predictors of prognosis in AML and, accordingly, are essential factors in the decision whether a patient should undergo bone marrow transplantation (1-4). These alterations have been set aside as determinants of independent diagnostic categories in WHO AML guidelines, and as essential for AML management in NCCN guidelines (5,6).

The contractor cites 31 sources in the bibliography; the full summary and analysis of evidence are in the CMS record.

Dates, lineage and related policies

Original determination effective
2018-08-01
Current revision effective
2026-04-01
Last reviewed by the contractor
2024-12-29
MCD version
18

The contractor lists 2 National Coverage Determinations as related: NCD 190.3 Cytogenetic Studies, NCD 90.2 Next Generation Sequencing (NGS). Where an NCD speaks, it controls; the LCD can only address what the NCD leaves open.

Other related documents: A59984 (Response to Comments).

Using this policy on a claim

Match the documented indication to the covered indications above before the service is scheduled, carry a diagnosis from the article's covered list on the claim line (the diagnosis coverage checker tests one code pair against every article that applies in a state), and keep the elements the documentation section asks for in the record, because the contractor can request it later through medical review. A denial under this policy arrives as CARC 50 with remark N115; the LCD lookup guide walks through the appeal path and the Advance Beneficiary Notice rules, and the Wellpoint Federal hub lists every other active policy from the same contractor.

For teams evaluating QuickIntell software

Where QuickIntell fits with this policy

If your team repeatedly reviews local coverage policies, explore QuickAuth for requirement checks, documentation and status tracking with staff oversight. Confirm the applicable policy, supported workflow and review responsibilities. Use QuickRCM to evaluate the separate claim and denial workflow.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions

What does LCD L37606 cover?

Genomic Sequential Analysis Panel will be considered reasonable and necessary in the evaluation of blood or bone marrow samples in the following clinical circumstances: The full 307-word policy text is reproduced below from the Medicare Coverage Database export of November 12, 2026.

Which states does LCD L37606 apply to?

Wellpoint Federal applies it to Medicare claims in 10 states: CT, IL, MA, ME, MN, NH, NY, RI, VT, WI. It binds only that contractor; outside these jurisdictions the same service is judged under the local contractor's own policy or, where none exists, claim by claim.

Which diagnosis codes support medical necessity under LCD L37606?

The companion billing and coding article A56793 lists 89 ICD-10-CM codes in 3 groups that support medical necessity; the first 24 appear on this page, where the complete list opens by group with the contractor's group instructions.

How do I appeal a denial under LCD L37606?

A denial under LCD L37606 carries claim adjustment reason code 50 with remark code N115. Compare the documented indication with the policy's covered indications and article A56793's 89 covered diagnosis codes, then file a redetermination with Wellpoint Federal within 120 days, record attached. If the service falls outside the policy, bill the patient only with a valid Advance Beneficiary Notice signed before the service.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

The policy text and code lists are reproduced from the CMS Medicare Coverage Database export as an operational reference. Verify against the current LCD and article on cms.gov before billing; coverage depends on the full record and the contractor. Not legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.